Home » AstraZeneca Launches Asthma Inhaler
AstraZeneca Launches Asthma Inhaler
AstraZeneca on Monday launched U.S. sales of its Symbicort twice-daily asthma inhaler. The inhaler, which is for the long-term maintenance treatment of asthma in patients ages 12 and older, will compete with GlaxoSmithKline’s Advair for a U.S. market estimated to be more than 20 million asthma patients.
Delawareonline
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May